Capital Research Global Investors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.7B Buy
24,632,647
+65,801
+0.3% +$66.7M 3.51% 5
2025
Q4
$26.4B Sell
24,566,846
-521,525
-2% -$499M 4.87% 4
2025
Q3
$19.1B Buy
25,088,371
+4,332,008
+21% +$3.22B 3.59% 5
2025
Q2
$16.2B Buy
20,756,363
+5,008,900
+32% +$3.89B 3.24% 6
2025
Q1
$13B Buy
15,747,463
+4,989,952
+46% +$4.15B 2.83% 5
2024
Q4
$8.3B Buy
10,757,511
+1,493,673
+16% +$1.24B 1.71% 10
2024
Q3
$8.21B Buy
9,263,838
+144,304
+2% +$130M 1.71% 10
2024
Q2
$8.26B Buy
9,119,534
+1,088,003
+14% +$870M 1.81% 11
2024
Q1
$6.25B Buy
8,031,531
+453,939
+6% +$323M 1.41% 11
2023
Q4
$4.42B Buy
7,577,592
+325,342
+4% +$190M 1.09% 20
2023
Q3
$3.9B Buy
7,252,250
+469,273
+7% +$242M 1.07% 24
2023
Q2
$3.18B Buy
6,782,977
+654,026
+11% +$274M 0.85% 27
2023
Q1
$2.1B Buy
6,128,951
+1,037,933
+20% +$350M 0.6% 44
2022
Q4
$1.86B Buy
5,091,018
+328,249
+7% +$116M 0.56% 50
2022
Q3
$1.54B Buy
4,762,769
+1,848,662
+63% +$586M 0.51% 54
2022
Q2
$945M Buy
+2,914,107
New +$875M 0.29% 80
2013
Q3
Sell
-800,000
Closed -$39.3M 452
2013
Q2
$39.3M Buy
+800,000
New +$43.5M 0.02% 343

Other funds holding LLY

Capital Research Global Investors's LLY Position: Q1 2026 in Review

Capital Research Global Investors increased its Eli Lilly (LLY) stake by 0.27% in Q1 2026, buying an estimated $66.7M and bringing the position to 24,632,647 shares worth $22.7B. The position accounts for 3.51% of the portfolio, ranked #5.

Capital Research Global Investors first reported a position in LLY in Q2 2013 and has held it in 17 quarters since. The position peaked at $26.4B in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capital Research Global Investors held 24,632,647 shares of Eli Lilly worth $22.7B as of Q1 2026.
  • Capital Research Global Investors bought 65,801 Eli Lilly shares in Q1 2026, an estimated $66.7M.
  • Eli Lilly made up 3.51% of Capital Research Global Investors's portfolio in Q1 2026, its #5 holding.
  • Capital Research Global Investors first reported a position in Eli Lilly in Q2 2013 and has held it in 17 quarters since.
  • Capital Research Global Investors's Eli Lilly position peaked at $26.4B in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.